Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
2.490
+0.120 (5.06%)
Oct 2, 2025, 3:54 PM EDT - Market open
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Inovio Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $8.80, which forecasts a 253.41% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $18.
Price Target: $8.80 (+253.41%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 14, 2025.
Analyst Ratings
The average analyst rating for Inovio Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $3 | Hold | Reiterates | $3 | +20.48% | Aug 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $5 | Buy | Initiates | $5 | +100.80% | Jul 9, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $5 | Hold | Reiterates | $5 | +100.80% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +422.09% | May 14, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | +100.80% | Mar 19, 2025 |
Financial Forecast
Revenue This Year
86.86K
from 217.76K
Decreased by -60.11%
Revenue Next Year
13.95M
from 86.86K
Increased by 15,960.33%
EPS This Year
-1.90
from -3.95
EPS Next Year
-1.54
from -1.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105,000 | 43.6M | |||
| Avg | 86,860 | 14.0M | |||
| Low | 63,700 | 1.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -51.8% | 50,091.1% | |||
| Avg | -60.1% | 15,960.3% | |||
| Low | -70.7% | 1,084.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.09 | -0.65 | |||
| Avg | -1.90 | -1.54 | |||
| Low | -2.26 | -1.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.